Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Ibrutinib in Japanese Subjects With Relapsed/Refractory Mantle Cell Lymphoma
NCT04477486Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in mantle cell lymphoma (MCL), sponsored by AbbVie Inc.. Started Sep 2020; status: completed.
02
Drugs
venetoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04477486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04477486.